A significant reduction in clinically relevant nonmajor bleeding was observed with tinzaparin ( 49 of 449 patients for tinzaparin vs 69 of 451 patients for warfarin ; HR , 0.58 [ 95 % CI , 0.40-0 .84 ] ; P = .004 ) .